Radiation oncology firm Elekta is highlighting a consortium it created to continue to develop the use of linear accelerator technologies for brain diseases.
The Elekta Linac-based Brain Stereotactic Radiation Therapy (SRT) Consortium's first priorities are to establish a linac-based SRT database; conduct research on practice patterns, contouring methods, and treatment-planning strategies; and publish large studies that investigate dose/fractionation, histology, local control and survival, and other parameters, the company said.
The group's founding members are Massachusetts General Hospital, Odette Cancer Centre at Sunnybrook Health Sciences Centre, the University of Iowa, and University Medical Center in Mannheim, Germany. Its first meeting was held on July 9 in Boston.
